Noa Therapeutics is on a mission to exceed the boundaries of current therapeutic approaches to deliver treatments with the greatest possible impact on patients living with chronic inflammatory diseases.
Unlike most therapeutics in the clinic and in development, which focus on downstream or adaptive immunity, Noa is restoring homeostasis to innate immune pathways to drive a deep and safe remission without the risk of global immunosuppression.
Through our safe and selective resolution of dysregulated transcriptional signaling pathways, Noa is focused on reestablishing immune and barrier homeostasis to eclipse the depth, breadth, and durability of current therapeutic options for inflammatory disease.
Company Details
- Employees
- 11
- Founded
- 2022
- Address
- 22 Adelaide Street West, Suite 3400,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.noatherapeutics.com
- HQ
- Toronto, Ontario
Noa Therapeutics Questions
Noa Therapeutics's website is http://www.noatherapeutics.com
Noa Therapeutics's LinkedIn profile is https://ca.linkedin.com/company/noa-therapeutics
Noa Therapeutics has
11 employees.
View email and phone details for 11
employees at Noa Therapeutics.
Noa Therapeutics's industry is
Biotechnology Research
Noa Therapeutics's top competitors are
Ripple Therapeutics,
Virica Biotech,
Dalriada Drug Discovery,
Seragene Therapeutics,
Omniabio,
Quthero,
Hdax Therapeutics,
Bluerock Therapeutics,
Obio,
Paradox Immunotherapeutics.
Noa Therapeutics's categories are Biotechnology Research
Noa Therapeutics's founding year is 2022
